Cancer-testis antigens and immunotherapy in the light of cancer complexity

F. Grizzi, L. Mirandola, D. Qehajaj, E. Cobos, J. A. Figueroa, M. Chiriva-Internati

Research output: Contribution to journalArticle

Abstract

The ability of immunotherapy to evoke successful antitumor immune responses has been well documented over the past decade. Despite abundant preclinical data, it is only with the recent approval by the Food and Drug Administration (FDA) of the drugs such as sipuleucel-T and ipilimumab that immunotherapy is finally being recognized as a viable alternative to traditional therapies for treatment of various cancers. Despite the ability of immunotherapy to elicit successful antitumor immune responses, its efficacy is hindered by several factors. Among these are the paucity of tumor-associated antigens (TAA) that can be used as effective targets and the systemic toxicities that often lead to treatment interruption. Indeed, such adverse effects, which can be immunological and/or parenchymal, can be particularly severe and even fatal to some patients. A family of TAA called cancer-testis antigens (CTA) has been identified and their encoding genes have been extensively investigated. CTA expression has been demonstrated in a variety of human cancer tissues, and at least 19 CTA have been found to elicit humoral and/or cellular immune responses in cancer patients. Here we discuss how CTA and immunotherapy will most likely play a major role in the cure of cancer in the light of cancer complexity.

Original languageEnglish
Pages (from-to)143-153
Number of pages11
JournalInternational Reviews of Immunology
Volume34
Issue number2
DOIs
Publication statusPublished - Mar 4 2015

Fingerprint

Testicular Neoplasms
Immunotherapy
Antigens
Neoplasm Antigens
Neoplasms
Drug Approval
Humoral Immunity
Cellular Immunity
Therapeutics
Genes

Keywords

  • Biomarkers
  • Cancer
  • Cancer-testis antigens
  • Immunotherapy
  • Inflammation
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Grizzi, F., Mirandola, L., Qehajaj, D., Cobos, E., Figueroa, J. A., & Chiriva-Internati, M. (2015). Cancer-testis antigens and immunotherapy in the light of cancer complexity. International Reviews of Immunology, 34(2), 143-153. https://doi.org/10.3109/08830185.2015.1018418

Cancer-testis antigens and immunotherapy in the light of cancer complexity. / Grizzi, F.; Mirandola, L.; Qehajaj, D.; Cobos, E.; Figueroa, J. A.; Chiriva-Internati, M.

In: International Reviews of Immunology, Vol. 34, No. 2, 04.03.2015, p. 143-153.

Research output: Contribution to journalArticle

Grizzi, F, Mirandola, L, Qehajaj, D, Cobos, E, Figueroa, JA & Chiriva-Internati, M 2015, 'Cancer-testis antigens and immunotherapy in the light of cancer complexity', International Reviews of Immunology, vol. 34, no. 2, pp. 143-153. https://doi.org/10.3109/08830185.2015.1018418
Grizzi, F. ; Mirandola, L. ; Qehajaj, D. ; Cobos, E. ; Figueroa, J. A. ; Chiriva-Internati, M. / Cancer-testis antigens and immunotherapy in the light of cancer complexity. In: International Reviews of Immunology. 2015 ; Vol. 34, No. 2. pp. 143-153.
@article{a874a0829d5440e88b07c20a1aa063a6,
title = "Cancer-testis antigens and immunotherapy in the light of cancer complexity",
abstract = "The ability of immunotherapy to evoke successful antitumor immune responses has been well documented over the past decade. Despite abundant preclinical data, it is only with the recent approval by the Food and Drug Administration (FDA) of the drugs such as sipuleucel-T and ipilimumab that immunotherapy is finally being recognized as a viable alternative to traditional therapies for treatment of various cancers. Despite the ability of immunotherapy to elicit successful antitumor immune responses, its efficacy is hindered by several factors. Among these are the paucity of tumor-associated antigens (TAA) that can be used as effective targets and the systemic toxicities that often lead to treatment interruption. Indeed, such adverse effects, which can be immunological and/or parenchymal, can be particularly severe and even fatal to some patients. A family of TAA called cancer-testis antigens (CTA) has been identified and their encoding genes have been extensively investigated. CTA expression has been demonstrated in a variety of human cancer tissues, and at least 19 CTA have been found to elicit humoral and/or cellular immune responses in cancer patients. Here we discuss how CTA and immunotherapy will most likely play a major role in the cure of cancer in the light of cancer complexity.",
keywords = "Biomarkers, Cancer, Cancer-testis antigens, Immunotherapy, Inflammation, Vaccine",
author = "F. Grizzi and L. Mirandola and D. Qehajaj and E. Cobos and Figueroa, {J. A.} and M. Chiriva-Internati",
year = "2015",
month = "3",
day = "4",
doi = "10.3109/08830185.2015.1018418",
language = "English",
volume = "34",
pages = "143--153",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Cancer-testis antigens and immunotherapy in the light of cancer complexity

AU - Grizzi, F.

AU - Mirandola, L.

AU - Qehajaj, D.

AU - Cobos, E.

AU - Figueroa, J. A.

AU - Chiriva-Internati, M.

PY - 2015/3/4

Y1 - 2015/3/4

N2 - The ability of immunotherapy to evoke successful antitumor immune responses has been well documented over the past decade. Despite abundant preclinical data, it is only with the recent approval by the Food and Drug Administration (FDA) of the drugs such as sipuleucel-T and ipilimumab that immunotherapy is finally being recognized as a viable alternative to traditional therapies for treatment of various cancers. Despite the ability of immunotherapy to elicit successful antitumor immune responses, its efficacy is hindered by several factors. Among these are the paucity of tumor-associated antigens (TAA) that can be used as effective targets and the systemic toxicities that often lead to treatment interruption. Indeed, such adverse effects, which can be immunological and/or parenchymal, can be particularly severe and even fatal to some patients. A family of TAA called cancer-testis antigens (CTA) has been identified and their encoding genes have been extensively investigated. CTA expression has been demonstrated in a variety of human cancer tissues, and at least 19 CTA have been found to elicit humoral and/or cellular immune responses in cancer patients. Here we discuss how CTA and immunotherapy will most likely play a major role in the cure of cancer in the light of cancer complexity.

AB - The ability of immunotherapy to evoke successful antitumor immune responses has been well documented over the past decade. Despite abundant preclinical data, it is only with the recent approval by the Food and Drug Administration (FDA) of the drugs such as sipuleucel-T and ipilimumab that immunotherapy is finally being recognized as a viable alternative to traditional therapies for treatment of various cancers. Despite the ability of immunotherapy to elicit successful antitumor immune responses, its efficacy is hindered by several factors. Among these are the paucity of tumor-associated antigens (TAA) that can be used as effective targets and the systemic toxicities that often lead to treatment interruption. Indeed, such adverse effects, which can be immunological and/or parenchymal, can be particularly severe and even fatal to some patients. A family of TAA called cancer-testis antigens (CTA) has been identified and their encoding genes have been extensively investigated. CTA expression has been demonstrated in a variety of human cancer tissues, and at least 19 CTA have been found to elicit humoral and/or cellular immune responses in cancer patients. Here we discuss how CTA and immunotherapy will most likely play a major role in the cure of cancer in the light of cancer complexity.

KW - Biomarkers

KW - Cancer

KW - Cancer-testis antigens

KW - Immunotherapy

KW - Inflammation

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84928572856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928572856&partnerID=8YFLogxK

U2 - 10.3109/08830185.2015.1018418

DO - 10.3109/08830185.2015.1018418

M3 - Article

C2 - 25901859

AN - SCOPUS:84928572856

VL - 34

SP - 143

EP - 153

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 2

ER -